Cover Image
市場調查報告書

泰國的醫藥品、醫療產業(季度更新報告)

Thailand Pharmaceuticals and Healthcare Report Q4 2016

出版商 BMI Research 商品編碼 243374
出版日期 內容資訊 英文 102 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
泰國的醫藥品、醫療產業(季度更新報告) Thailand Pharmaceuticals and Healthcare Report Q4 2016
出版日期: 2016年10月26日 內容資訊: 英文 102 Pages
簡介

本報告提供泰國的製藥、醫療產業結構和最新趨勢相關分析,今後10年的產業規模動向估計,產業的課題(風險)和未來商機(利潤)相關評估,政府的政策、規定,宏觀經濟環境,主要企業簡介等資訊彙整,為您概述為以下內容。

BMI的見解

SWOT分析

產業預測

  • 醫藥品市場預測
  • 醫療市場預測
  • 處方藥市場預測
  • 專利藥市場預測
  • 學名藥市場預測
  • 一般用(OTC)醫藥品市場預測
  • 醫藥品的對外貿易情形

產業的風險/利潤、目錄

  • 亞太地區:風險/利潤、目錄
  • 泰國:風險/利潤、目錄
    • 利潤
    • 風險

法規概要

  • 知識產權(IP)的問題
  • 價格設定
  • 醫療費償付

市場概況

  • 醫療部門
  • 研究開發(R&D)部門
  • 臨床實驗
  • 流行病學

競爭環境

  • 研究開發意向型產業
  • 學名藥廠商
  • 醫藥品的批發業
  • 醫藥品的零售業

企業簡介

  • Berlin Pharmaceutical Industry
  • Biolab
  • GlaxoSmithKline
  • Government Pharmaceutical Organisation
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi

人口結構的預測

詞彙表

分析方法

  • 醫藥品支出額的預測模式
  • 醫療費的預測模式
  • 分析方法的相關註記
  • 風險/利潤、目錄技術
  • 目錄概要
  • 指標的加權

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 1748-2240

BMI View: Reforms to Thailand's healthcare system will influence the commercial opportunities for multinational drugmakers. While a merger of all three schemes remains difficult, incremental reforms in that direction will be forthcoming and necessary for Thailand to address inequalities in healthcare outcomes. Pressures to ensure the sustainability of the country's healthcare programmes have also not abated. This accentuates the threat of cost containment for drugmakers, which will be heightened should Thailand pursue the target - set by the Committee on Resource Mobilisation for Sustainable Universal Health Coverage - of keeping total health spending less than 5% of GDP by 2022.

Headline Expenditure Projections

  • Pharmaceuticals: THB153bn (USD4.5bn) in 2015 to THB161bn (USD4.6bn) in 2016; +5.3% in local currency terms and +1.9% in US dollar terms.
  • Healthcare: THB841bn (USD24bn) in 2015 to THB892bn (USD25bn) in 2016: +6.1% in local currency and +2.6% in US dollar terms.

Risk/Reward Index

In Q416, Thailand remains in the lower half of the Pharmaceutical Risk/Reward Index table that assesses the attractiveness of 19 countries in the Asia Pacific region, with a score of 49.3 out of 100. While Thailand offers relatively attractive revenue-earning opportunities in a regional-comparison for multinational investors, increasing pharmaceutical expenditure is somewhat overshadowed by the prevalent risks in the country including low levels of patent protection.

Table of Contents

BMI Industry View

  • Table: Headline Pharmaceuticals & Healthcare Forecasts (Thailand 2014-2020)

SWOT

Industry Forecast

  • Pharmaceutical Market Forecast
    • Table: Pharmaceutical Sales, Historical Data And Forecasts (Thailand 2012-2020)
  • Healthcare Market Forecast
    • Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
    • Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
    • Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Thailand 2012-2020)
  • Prescription Drug Market Forecast
    • Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Patented Drug Market Forecast
    • Table: Patented Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Generic Drug Market Forecast
    • Table: Generic Drug Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • OTC Drug Market Forecast
    • Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Thailand 2012-2020)
  • Pharmaceutical Trade Forecast
    • Table: Pharmaceutical Trade Data And Forecasts (Thailand 2014-2020)
    • Table: Pharmaceutical Trade Data And Forecasts local currency (Thailand 2014-2020)

Industry Risk/Reward Index

  • Asia Pacific Risk/Reward Index - Q4 2016
  • Thailand Risk/Reward Index
    • Rewards
    • Risks

Regulatory Review

  • Intellectual Property Issues
  • Pricing Regime
    • Table: Price Build-Up Of Medicines In Thailand
  • Reimbursement Regime

Market Overview

  • Healthcare Sector
    • Table: Major Health Insurance Programmes In Thailand
    • Table: Healthcare Resources (Thailand 2010-2015)
    • Table: Healthcare Personnel (Thailand 2010-2015)
    • Table: Healthcare Activity (Thailand 2010-2015)
  • Research & Development
  • Clinical Trials
  • Epidemiology
    • Table: Estimated Number Of New Cases Of Cancer In Thailand

Competitive Landscape

  • Research-Based Industry
    • Table: PReMA Members
    • Table: Multinational Market Activity
  • Generic Drugmakers
    • Table: Pharmaceutical Manufacturers Of Modern Drugs, 2007-2012
  • Pharmaceutical Distribution
  • Pharmaceutical Retail Sector

Company Profile

  • Berlin Pharmaceutical Industry
  • Biolab
  • GlaxoSmithKline
  • Government Pharmaceutical Organisation
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi

Demographic Forecast

  • Table: Population Headline Indicators (Thailand 1990-2025)
  • Table: Key Population Ratios (Thailand 1990-2025)
  • Table: Urban/Rural Population & Life Expectancy (Thailand 1990-2025)
  • Table: Population By Age Group (Thailand 1990-2025)
  • Table: Population By Age Group % (Thailand 1990-2025)

Glossary

Methodology

  • Pharmaceutical Expenditure Forecast Model
  • Healthcare Expenditure Forecast Model
  • Notes On Methodology
  • Risk/Reward Index Methodology
  • Index Overview
    • Table: Pharmaceutical Risk/Reward Index Indicators
  • Indicator Weightings
Back to Top